TagsOncology 
Turning RCC to Rejoice, Courage, and Care: A Review on the Management of Renal Cell Carcinoma and the Related Innovations

Renal cell carcinomas (RCCs) are the most common type of kidney cancer in adults and is prevalent in adult male aged between 60 and 70. Notably, clear cell RCC (ccRCC) is the most abundant subtype of RCC with the worse disease-specific survival as i...

Feb 6, 2024
Trodelvy

Trodelvy (sacituzumab govitecan) Gilead Presentation: Each vial contains 180 mg of Sacituzumab govitecan. Off-white to yellowish lyophilized powder in a single-dose vial. Indications: Trodelvy is indicated for the treatment of adult patients wit...

Dec 18, 2023
Exkivity

Exkivity® ( mobocertinib ) 1-3 Takeda Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that selectively inhibits and irreversibly binds to EGFR exon 20 insertion mutations at lower concentrations than Wild type (...

Jun 13, 2023
Cancer Cells Use Uridine-derived Ribose as Fuel when Starved

Pancreatic ductal adenocarcinoma (PDA) is called a silent killer, as it is often discovered late and has a high mortality rate. Its treatment-resistant and aggressive nature can be attributed to the tumour microenvironment, low vascularity, and meta...

Jun 13, 2023
The New Age of Colorectal Cancer

Existing Knowledge on Colorectal Cancer Colorectal cancer (CRC) is the third most common type of cancer and second most common cause of cancer-related deaths globally 1 . There were over 1.9 million new cases of CRC globally in 2020 with medium to h...

Jun 13, 2023
The Promising Fixed-duration Oral Regimen for Older and Unfit Patients with Chronic Lymphocytic Leukaemia

Chronic lymphocytic leukaemia (CLL) is a chronic lymphoproliferative disorder characterised by proliferation of monoclonal mature B-cells in peripheral blood, bone marrow, and secondary lymphoid tissues, such as spleen and lymph nodes 1 . The incide...

Jun 13, 2023
Hybrid Lecture on Management of Relapsed or Refractory Multiple Myeloma

The management of relapsed and refractory multiple myeloma (RRMM) continues to be challenging though new therapeutics for the disease have been emerging in recent decades. Essentially, while decreased survival was observed in each extra line of ther...

Mar 17, 2022
Proven Benefits of IMiDs-based Regimen in Managing Multiple Myeloma

Currently Available Therapeutic Options for MM MM is currently one of the most prevalent haematological malignancies, which mainly affects individuals aged above 65 2 , a relatively vulnerable group of patients owing to comorbidities and immunosenes...

Dec 20, 2021
Therapeutic Sequencing Strategy in Multiple Myeloma

The Multitude of Activities of IMiDs Because of the established benefits, IMiDs are recommended as induction therapy for both transplant eligible and ineligible patients, in the post-transplant maintenance setting, and for relapsed/refractory diseas...

Dec 20, 2021
Pomalidomide in Lenalidomide-refractory Multiple Myeloma

Background Information The patient of the current case was a 64-year-old male with documented ischemic heart disease and received 3 times of percutaneous coronary intervention (PCI), respectively in 2004, 2005 and 2013. In 2015, the patient complain...

Dec 20, 2021
Keep the Gut Out of Mischief The Advancement in Diagnosis for Colorectal Cancer

Where Are We in the Prevention of CRC? Ageing and male gender are common risk factors for CRC. In addition, a positive family history, a history of familial adenomatous polyposis, occurrence of Lynch syndrome, development of colonic polyp, and ulcer...

Dec 20, 2021
Exploring Chemotherapy-associated Cognitive Impairment in Colorectal Cancer

Exploring Chemotherapy-associated Cognitive Impairment in Colorectal Cancer Chemotherapy, which is commonplace in treating a plethora of cancers, has seen increasing concerns over its possible role in inducing cognitive impairment 1 . In breast canc...

Dec 20, 2021